• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒抗体反应的表位解析分析确定了与地方性人类冠状病毒的交叉反应性。

Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses.

作者信息

Ladner Jason T, Henson Sierra N, Boyle Annalee S, Engelbrektson Anna L, Fink Zane W, Rahee Fatima, D'ambrozio Jonathan, Schaecher Kurt E, Stone Mars, Dong Wenjuan, Dadwal Sanjeet, Yu Jianhua, Caligiuri Michael A, Cieplak Piotr, Bjørås Magnar, Fenstad Mona H, Nordbø Svein A, Kainov Denis E, Muranaka Norihito, Chee Mark S, Shiryaev Sergey A, Altin John A

机构信息

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.

The Translational Genomics Research Institute (TGen), Phoenix and Flagstaff, AZ, USA.

出版信息

Cell Rep Med. 2021 Jan 19;2(1):100189. doi: 10.1016/j.xcrm.2020.100189.

DOI:10.1016/j.xcrm.2020.100189
PMID:33495758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7816965/
Abstract

The SARS-CoV-2 proteome shares regions of conservation with endemic human coronaviruses (CoVs), but it remains unknown to what extent these may be cross-recognized by the antibody response. Here, we study cross-reactivity using a highly multiplexed peptide assay (PepSeq) to generate an epitope-resolved view of IgG reactivity across all human CoVs in both COVID-19 convalescent and negative donors. PepSeq resolves epitopes across the SARS-CoV-2 Spike and Nucleocapsid proteins that are commonly targeted in convalescent donors, including several sites also recognized in some uninfected controls. By comparing patterns of homologous reactivity between CoVs and using targeted antibody-depletion experiments, we demonstrate that SARS-CoV-2 elicits antibodies that cross-recognize pandemic and endemic CoV antigens at two Spike S2 subunit epitopes. We further show that these cross-reactive antibodies preferentially bind endemic homologs. Our findings highlight sites at which the SARS-CoV-2 response appears to be shaped by previous CoV exposures and which have the potential to raise broadly neutralizing responses.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的蛋白质组与地方性人类冠状病毒(CoV)存在保守区域,但这些区域在多大程度上会被抗体反应交叉识别仍不清楚。在这里,我们使用一种高度多重的肽分析方法(PepSeq)研究交叉反应性,以生成新冠康复者和阴性捐赠者中所有人类冠状病毒IgG反应性的表位解析视图。PepSeq解析了SARS-CoV-2刺突蛋白和核衣壳蛋白上的表位,这些表位是康复者中常见的靶点,包括一些在一些未感染对照中也被识别的位点。通过比较不同冠状病毒之间的同源反应模式并进行靶向抗体去除实验,我们证明SARS-CoV-2在刺突蛋白S2亚基的两个表位上引发了交叉识别大流行和地方性冠状病毒抗原的抗体。我们进一步表明,这些交叉反应性抗体优先结合地方性同源物。我们的研究结果突出了一些位点,在这些位点上,SARS-CoV-2反应似乎受到先前冠状病毒暴露的影响,并且有可能引发广泛的中和反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/98c80d37a7b9/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/2195b15c7d57/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/b1981d3c7637/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/cc08668c84af/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/9873479700fc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/98c80d37a7b9/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/2195b15c7d57/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/b1981d3c7637/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/cc08668c84af/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/9873479700fc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee29/7817865/98c80d37a7b9/gr4.jpg

相似文献

1
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses.新冠病毒抗体反应的表位解析分析确定了与地方性人类冠状病毒的交叉反应性。
Cell Rep Med. 2021 Jan 19;2(1):100189. doi: 10.1016/j.xcrm.2020.100189.
2
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗体反应的表位解析分析确定了与一种地方性人类冠状病毒的交叉反应性。
bioRxiv. 2020 Jul 27:2020.07.27.222943. doi: 10.1101/2020.07.27.222943.
3
COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins.COVID-19 疫苗接种会引起针对与地方性冠状病毒刺突蛋白保守表位的不断进化、交叉反应的抗体反应。
Cell Rep. 2022 Jul 5;40(1):111022. doi: 10.1016/j.celrep.2022.111022. Epub 2022 Jun 13.
4
COVID-19 vaccination recruits and matures cross-reactive antibodies to conserved epitopes in endemic coronavirus Spike proteins.新冠病毒疫苗接种可募集并成熟针对地方性冠状病毒刺突蛋白中保守表位的交叉反应性抗体。
medRxiv. 2022 Jan 25:2022.01.24.22269542. doi: 10.1101/2022.01.24.22269542.
5
Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.用于检测 COVID-19 恢复期血浆中 SARS-CoV-2 特异性 IgG 的多重冠状病毒抗原阵列的评估。
J Immunol Methods. 2021 Oct;497:113104. doi: 10.1016/j.jim.2021.113104. Epub 2021 Jul 22.
6
The landscape of antibody binding in SARS-CoV-2 infection.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中抗体结合的情况
bioRxiv. 2021 Jan 8:2020.10.10.334292. doi: 10.1101/2020.10.10.334292.
7
Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和地方性冠状病毒感染中的刺突蛋白的交叉反应性血清和记忆B细胞反应。
bioRxiv. 2020 Sep 23:2020.09.22.308965. doi: 10.1101/2020.09.22.308965.
8
Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.评估中东呼吸综合征冠状病毒与其他冠状病毒之间的血清学和抗原关系,以开发疫苗平台,快速应对新出现的冠状病毒。
J Infect Dis. 2014 Apr 1;209(7):995-1006. doi: 10.1093/infdis/jit609. Epub 2013 Nov 18.
9
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.新冠病毒感染 14 个月后 COVID-19 恢复期患者结合抗体和中和抗体的动态分析。
Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.
10
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.利用 MultiCoV-Ab 探索临床常规 SARS-CoV-2 血清学以外的方法,以评估地方性冠状病毒的交叉反应性。
Nat Commun. 2021 Feb 19;12(1):1152. doi: 10.1038/s41467-021-20973-3.

引用本文的文献

1
Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus.疫苗预防策略对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒变体的适应性
Vaccines (Basel). 2025 Jul 17;13(7):761. doi: 10.3390/vaccines13070761.
2
Aging and Viral Evolution Impair Immunity Against Dominant Pan-Coronavirus-Reactive T Cell Epitope.衰老和病毒进化削弱针对主要泛冠状病毒反应性T细胞表位的免疫力。
Eur J Immunol. 2025 Jul;55(7):e51888. doi: 10.1002/eji.202551888.
3
PepSeq as a highly multiplexed platform for melioidosis antigen discovery and vaccine development.

本文引用的文献

1
Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植受者的季节性人冠状病毒呼吸道感染。
J Infect Dis. 2021 May 20;223(9):1564-1575. doi: 10.1093/infdis/jiaa553.
2
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.一种基于抗体介导的 ACE2-刺突蛋白-蛋白相互作用阻断的 SARS-CoV-2 假病毒中和试验。
Nat Biotechnol. 2020 Sep;38(9):1073-1078. doi: 10.1038/s41587-020-0631-z. Epub 2020 Jul 23.
3
Potently neutralizing and protective human antibodies against SARS-CoV-2.
肽序列分析作为一种用于类鼻疽抗原发现和疫苗开发的高度多重化平台。
Front Immunol. 2025 Jul 3;16:1605758. doi: 10.3389/fimmu.2025.1605758. eCollection 2025.
4
Minimal Impact of Prior Common Cold Coronavirus Exposure on Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination or Infection Risk in Older Adults in Congregate Care.既往普通感冒冠状病毒暴露对老年集体照护机构中老年人严重急性呼吸综合征冠状病毒2疫苗接种免疫反应或感染风险的影响极小。
Open Forum Infect Dis. 2025 May 1;12(5):ofaf178. doi: 10.1093/ofid/ofaf178. eCollection 2025 May.
5
Vaccination versus natural infection: A review of antibody differentiation techniques.疫苗接种与自然感染:抗体鉴别技术综述
J Res Med Sci. 2025 Mar 29;30:18. doi: 10.4103/jrms.jrms_550_24. eCollection 2025.
6
Distinct immune responses in people living with HIV following SARS-CoV-2 recovery.SARS-CoV-2感染康复后的HIV感染者的不同免疫反应。
Commun Med (Lond). 2025 Apr 23;5(1):132. doi: 10.1038/s43856-025-00839-1.
7
Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles.重症新型冠状病毒肺炎(COVID-19)期间输血后凝血途径的激活与COVID-19康复期血浆抗体谱相关。
J Clin Invest. 2025 Mar 17;135(6):e181136. doi: 10.1172/JCI181136.
8
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.被动输注一种S2茎区广泛中和抗体可保护恒河猴免受SARS-CoV-2感染并减轻下呼吸道炎症。
PLoS Pathog. 2025 Jan 23;21(1):e1012456. doi: 10.1371/journal.ppat.1012456. eCollection 2025 Jan.
9
Clinical symptoms, comorbidities and health outcomes among outpatients infected with the common cold coronaviruses versus influenza virus.门诊感染普通感冒冠状病毒与流感病毒患者的临床症状、合并症和健康结局。
Virol J. 2024 Oct 8;21(1):251. doi: 10.1186/s12985-024-02524-6.
10
Severe acute respiratory syndrome coronavirus 2-reactive salivary antibody detection in South Carolina emergency healthcare workers, September 2019-March 2020.2019 年 9 月至 2020 年 3 月,南卡罗来纳州急诊医护人员中严重急性呼吸综合征冠状病毒 2 反应性唾液抗体的检测。
Epidemiol Infect. 2024 Sep 25;152:e102. doi: 10.1017/S0950268824000967.
强效中和和保护 SARS-CoV-2 的人源抗体。
Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub 2020 Jul 15.
4
Antibody responses against SARS-CoV-2 in COVID-19 patients.COVID-19患者针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗体反应。
J Med Virol. 2021 Jan;93(1):144-148. doi: 10.1002/jmv.26241. Epub 2020 Aug 2.
5
Antibody tests for identification of current and past infection with SARS-CoV-2.用于识别当前和既往感染新型冠状病毒2的抗体检测。
Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652.
6
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.一种中和性人源抗体结合到了 SARS-CoV-2 的刺突蛋白的 N 端结构域。
Science. 2020 Aug 7;369(6504):650-655. doi: 10.1126/science.abc6952. Epub 2020 Jun 22.
7
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.恢复期患者体内对 SARS-CoV-2 的趋同抗体反应
Nature. 2020 Aug;584(7821):437-442. doi: 10.1038/s41586-020-2456-9. Epub 2020 Jun 18.
8
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.在人源化小鼠和恢复期患者中的研究产生了一种 SARS-CoV-2 抗体鸡尾酒。
Science. 2020 Aug 21;369(6506):1010-1014. doi: 10.1126/science.abd0827. Epub 2020 Jun 15.
9
Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.抗体依赖的感染增强对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)应对措施的影响。
Nat Biotechnol. 2020 Jul;38(7):789-791. doi: 10.1038/s41587-020-0577-1.
10
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.COVID-19 患者体内诱导中和抗体的 SARS-CoV-2 刺突蛋白上的两个线性表位。
Nat Commun. 2020 Jun 1;11(1):2806. doi: 10.1038/s41467-020-16638-2.